{
  "id": 6179380,
  "title": "Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock?",
  "url": "https://urgent.news/2026/09/07/eli-lilly-has-been-on-an-acquisition-spree-how-much-could-its-latest",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-07T21:15:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/09/07/eli-lilly-has-been-on-an-acquisition-spree-how-muc/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Eli Lilly is engaged in an acquisition frenzy, and the impact of its latest deals on the stock price remains uncertain. However, these acquisitions could serve as the groundwork for the pharmaceutical giant's future growth. To understand the company's current situation, it is essential to examine its second-quarter revenues. Mounjaro, Zepbound, and Foundayo are responsible for nearly two-thirds of Eli Lilly's top line. These drugs target the same health issue: weight loss. Despite being a drug maker, Eli Lilly's success lies in its weight-loss drugs, which have become crucial products for the company.",
  "summary": "The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock?",
        "url": "https://urgent.news/2026/09/07/eli-lilly-has-been-on-an-acquisition-spree-how-much-could-its-latest-6180726",
        "published": "2026-09-07T21:35:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}